Stay updated on Galegenimab in Geographic Atrophy AMD: Clinical Trial

Sign up to get notified when there's something new on the Galegenimab in Geographic Atrophy AMD: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Galegenimab in Geographic Atrophy AMD: Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study's progress or data related to the safety, tolerability, and efficacy of intravitreal injections of galegenimab in participants with geographic atrophy secondary to age-related macular degeneration.
    Difference
    0.1%
    Check dated 2024-06-06T14:31:59.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying age, visual acuity, and health conditions. Previously, this section had no information provided.
    Difference
    14%
    Check dated 2024-05-22T20:57:58.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:39:59.000Z thumbnail image

Stay in the know with updates to Galegenimab in Geographic Atrophy AMD: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Galegenimab in Geographic Atrophy AMD: Clinical Trial page.